AIM: To assess the effect of artificial liver support system(ALSS) on patients with severe viral hepatitis, who were divided into treatment group and control group. METHODS: Four hundred in-hospital patients enrolled ...AIM: To assess the effect of artificial liver support system(ALSS) on patients with severe viral hepatitis, who were divided into treatment group and control group. METHODS: Four hundred in-hospital patients enrolled during 1995-2003 who received ALSS therapy were studied as the treatment group. Four hundred in-hospital patients enrolled during 1986-1994 who received other medical therapies served as the control group. The methods of ALSS used included plasma exchange, hemoperfusion, hemofiltration, continuous hemodiafiltration (CHDF). The effect of ALSS treatment was studied in patients at different stages of the disease.RESULTS: The cure rate of acute and subacute severe hepatitis in the treatment group was 78.9% (30/38), and was 11.9% (5/42) in the control group. The improved rate of chronic severe hepatitis in the treatment group was 43.4% (157/362), and was 15.4% (55/358) in the control group. We found that patients treated with ALSS in the early or middle stage of the disease had much higher survival rates than patients in the end stage of the disease. CONCLUSION: ALSS is an effective and safe therapy for severe viral hepatitis.展开更多
AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failure patients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioart...AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failure patients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioartificial liver could support liver functions or not.METHODS: Hepatocytes were procured from swine using Seglen′s methods. The bioartificial liver was constructed by polysulfon bioreactor and more than 10 10 hepatocytes. It was applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HBAL and 5 cases of nonsimultaneous HBAL. Each BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied.RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showed significant decrease. 2 days later, blood ammonia still showed improvment. within one month period, 1 case (1/7) in simultaneous group died while in non-simultaneous group 2 cases (2/5) died. The difference was significant. Mortality rate was 25 %.CONCLUSION: The constructed bioartificial liver can support liver functions in acute liver failure. The simultaneous HBAL is better than non-simultaneous HBAL.展开更多
目的:观察血浆置换(plasma exchange,PE)、血浆胆红素吸附(plasma specific bilirubin adsorption,PBA)与PE+PBA(联合组)治疗乙型肝炎肝衰竭的临床疗效,探讨乙型肝炎肝衰竭的最佳人工肝治疗方法.方法:回顾性分析乙型肝炎肝衰竭患者150例...目的:观察血浆置换(plasma exchange,PE)、血浆胆红素吸附(plasma specific bilirubin adsorption,PBA)与PE+PBA(联合组)治疗乙型肝炎肝衰竭的临床疗效,探讨乙型肝炎肝衰竭的最佳人工肝治疗方法.方法:回顾性分析乙型肝炎肝衰竭患者150例,分为PE组、PBA组、联合组,观察3组患者治疗前后丙氨酸转氨酶(alanine aminotransferase,ALT)、总胆红素(total bilirubin,TBIL)、白蛋白(albumin,ALB)、凝血酶原时间(prothrombin time,PT)、凝血酶原时间活动度(prothrombin time activity,PTA)、肌酐(creatinine,Cr)和血氨的水平,并观察不良反应的发生率.结果:(1)联合组总有效率65.45%,高于PE组和PBA组的62.5%和59.58%,但差异无统计学意义(P>0.05);(2)PE组、PBA组、联合组患者治疗前及治疗后4hTBIL分别为:410.3mol/L±208.6mol/Lvs292.5mol/L±175.4mol/L,432.7mol/L±242.5mol/Lvs298.8mol/L±201.7mol/L,468.2mol/L±241.6mol/Lvs288.5mol/L±184.5mol/L,治疗后3组TBIL均明显下降(P<0.05),下降幅度3组间差异无意义;(3)联合组和PE组治疗后PT缩短,PTA升高(P<0.05),两组间差异无意义(P>0.05);(4)3组患者治疗后血氨均显著降低(P<0.05),但3组间无显著统计学差异(P>0.05);(5)3组患者治疗后Cr均下降(P<0.05),但3组间差异无统计学意义(P>0.05);(6)未发生严重不良反应;(7)单次血浆用量,联合组1107.1mL±212.3mL,明显少于PE组的2911.5mL±352.3mL(P<0.05).结论:PE+PBA应用血浆量少,治疗乙型肝炎肝衰竭安全、有效.展开更多
目的评价血浆置换(PE)治疗重型肝炎的疗效及安全性。方法回顾性分析69名重型肝炎患者的临床资料,按其治疗方式的不同分为治疗(PE)组:39名,在内科综合治疗基础上行血浆置换;对照组:30名,单纯内科综合治疗。于治疗前、后24 h检测PE组患者...目的评价血浆置换(PE)治疗重型肝炎的疗效及安全性。方法回顾性分析69名重型肝炎患者的临床资料,按其治疗方式的不同分为治疗(PE)组:39名,在内科综合治疗基础上行血浆置换;对照组:30名,单纯内科综合治疗。于治疗前、后24 h检测PE组患者的凝血酶原时间(PT)、凝血酶时间(TT)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(T-BILI)、直接胆红素(D-BILI)和总胆汁酸(TBA)等生化指标的变化;同时观察2组患者的临床症状及体征的改变,评价整体疗效,并在统计分析患者病情分期、并发症与血浆置换治疗重型肝炎疗效的关系后,做出临床评判。结果 1)PE组治疗前后凝血功能和肝功能生化指标分别为:PT(s)24.5±9.19 vs17.8±6.71、TT(s)16.6±3.87 vs 17.9±11.82、ALT(U/L)281.2±271.16 vs 69.4±91.97、AST(U/L)285.8±247.91vs 64.8±43.94、T-BILI(μmol/L)407.0±178.99 vs 238.2±143.76、D-BILI(μmol/L)316.1±131.09 vs 167.4±110.85、TBA(μmol/L)141.7±83.56 vs 140.6±86.26;2)总体有效率(%),PE与对照组为56.41 vs 30.00,其中早、中、晚期的重型肝炎有效率分别为81.25 vs 41.67、53.85 vs 40.00、20.00 vs 12.50(P<0.05);3)并发自发性腹膜炎的患者治疗后的有效率(%),PE与对照组分别为70.00 vs 40.00。结论 PE是治疗重型肝炎的1种安全、有效方法;对于早期重症肝炎患者疗效优于中晚期重症肝炎患者,对合并自发性腹膜炎患者的疗效优于单纯内科综合疗法。展开更多
基金Supported by the National High Technology Research and Development Program of China (863 Program),No.2003AA205015 and the Major Science Foundation of Zhejiang Province,No.021107689 and No.021103126 and the Health Foundation of Zhejiang Province,No.2003A0
文摘AIM: To assess the effect of artificial liver support system(ALSS) on patients with severe viral hepatitis, who were divided into treatment group and control group. METHODS: Four hundred in-hospital patients enrolled during 1995-2003 who received ALSS therapy were studied as the treatment group. Four hundred in-hospital patients enrolled during 1986-1994 who received other medical therapies served as the control group. The methods of ALSS used included plasma exchange, hemoperfusion, hemofiltration, continuous hemodiafiltration (CHDF). The effect of ALSS treatment was studied in patients at different stages of the disease.RESULTS: The cure rate of acute and subacute severe hepatitis in the treatment group was 78.9% (30/38), and was 11.9% (5/42) in the control group. The improved rate of chronic severe hepatitis in the treatment group was 43.4% (157/362), and was 15.4% (55/358) in the control group. We found that patients treated with ALSS in the early or middle stage of the disease had much higher survival rates than patients in the end stage of the disease. CONCLUSION: ALSS is an effective and safe therapy for severe viral hepatitis.
基金the Public Health Bureau of Jiangsu Province,China, BQ200020Social Development Plan of Scientific and Technological Council of Nanjing Municipal,China.SS200002
文摘AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failure patients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioartificial liver could support liver functions or not.METHODS: Hepatocytes were procured from swine using Seglen′s methods. The bioartificial liver was constructed by polysulfon bioreactor and more than 10 10 hepatocytes. It was applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HBAL and 5 cases of nonsimultaneous HBAL. Each BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied.RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showed significant decrease. 2 days later, blood ammonia still showed improvment. within one month period, 1 case (1/7) in simultaneous group died while in non-simultaneous group 2 cases (2/5) died. The difference was significant. Mortality rate was 25 %.CONCLUSION: The constructed bioartificial liver can support liver functions in acute liver failure. The simultaneous HBAL is better than non-simultaneous HBAL.
文摘目的:观察血浆置换(plasma exchange,PE)、血浆胆红素吸附(plasma specific bilirubin adsorption,PBA)与PE+PBA(联合组)治疗乙型肝炎肝衰竭的临床疗效,探讨乙型肝炎肝衰竭的最佳人工肝治疗方法.方法:回顾性分析乙型肝炎肝衰竭患者150例,分为PE组、PBA组、联合组,观察3组患者治疗前后丙氨酸转氨酶(alanine aminotransferase,ALT)、总胆红素(total bilirubin,TBIL)、白蛋白(albumin,ALB)、凝血酶原时间(prothrombin time,PT)、凝血酶原时间活动度(prothrombin time activity,PTA)、肌酐(creatinine,Cr)和血氨的水平,并观察不良反应的发生率.结果:(1)联合组总有效率65.45%,高于PE组和PBA组的62.5%和59.58%,但差异无统计学意义(P>0.05);(2)PE组、PBA组、联合组患者治疗前及治疗后4hTBIL分别为:410.3mol/L±208.6mol/Lvs292.5mol/L±175.4mol/L,432.7mol/L±242.5mol/Lvs298.8mol/L±201.7mol/L,468.2mol/L±241.6mol/Lvs288.5mol/L±184.5mol/L,治疗后3组TBIL均明显下降(P<0.05),下降幅度3组间差异无意义;(3)联合组和PE组治疗后PT缩短,PTA升高(P<0.05),两组间差异无意义(P>0.05);(4)3组患者治疗后血氨均显著降低(P<0.05),但3组间无显著统计学差异(P>0.05);(5)3组患者治疗后Cr均下降(P<0.05),但3组间差异无统计学意义(P>0.05);(6)未发生严重不良反应;(7)单次血浆用量,联合组1107.1mL±212.3mL,明显少于PE组的2911.5mL±352.3mL(P<0.05).结论:PE+PBA应用血浆量少,治疗乙型肝炎肝衰竭安全、有效.
文摘目的评价血浆置换(PE)治疗重型肝炎的疗效及安全性。方法回顾性分析69名重型肝炎患者的临床资料,按其治疗方式的不同分为治疗(PE)组:39名,在内科综合治疗基础上行血浆置换;对照组:30名,单纯内科综合治疗。于治疗前、后24 h检测PE组患者的凝血酶原时间(PT)、凝血酶时间(TT)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(T-BILI)、直接胆红素(D-BILI)和总胆汁酸(TBA)等生化指标的变化;同时观察2组患者的临床症状及体征的改变,评价整体疗效,并在统计分析患者病情分期、并发症与血浆置换治疗重型肝炎疗效的关系后,做出临床评判。结果 1)PE组治疗前后凝血功能和肝功能生化指标分别为:PT(s)24.5±9.19 vs17.8±6.71、TT(s)16.6±3.87 vs 17.9±11.82、ALT(U/L)281.2±271.16 vs 69.4±91.97、AST(U/L)285.8±247.91vs 64.8±43.94、T-BILI(μmol/L)407.0±178.99 vs 238.2±143.76、D-BILI(μmol/L)316.1±131.09 vs 167.4±110.85、TBA(μmol/L)141.7±83.56 vs 140.6±86.26;2)总体有效率(%),PE与对照组为56.41 vs 30.00,其中早、中、晚期的重型肝炎有效率分别为81.25 vs 41.67、53.85 vs 40.00、20.00 vs 12.50(P<0.05);3)并发自发性腹膜炎的患者治疗后的有效率(%),PE与对照组分别为70.00 vs 40.00。结论 PE是治疗重型肝炎的1种安全、有效方法;对于早期重症肝炎患者疗效优于中晚期重症肝炎患者,对合并自发性腹膜炎患者的疗效优于单纯内科综合疗法。
